The current stock price of MTFB is 0.105 null. In the past month the price decreased by -33.92%. In the past year, price decreased by -98.25%.
Motif Bio plc is a biopharmaceutical company. It engaged in the research and development of antibiotics for serious and life-threatening infections caused by multi-drug resistant bacteria. The company's product pipeline includes Iclaprim, REVIVE-1 and REVIVE-2 which are in clinical stage. Motif Bio plc is headquartered in London, UK.
Motif Bio Plc
201 TEMPLE CHAMBERS 3-7 TEMPLE AVENUE
LONDON X0 EC4Y0DT
CEO: Graham George Lumsden
Phone: 212-210-6248
Motif Bio plc is a biopharmaceutical company. It engaged in the research and development of antibiotics for serious and life-threatening infections caused by multi-drug resistant bacteria. The company's product pipeline includes Iclaprim, REVIVE-1 and REVIVE-2 which are in clinical stage. Motif Bio plc is headquartered in London, UK.
The current stock price of MTFB is 0.105 null. The price decreased by -4.63% in the last trading session.
MTFB does not pay a dividend.
MTFB has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
MTFB stock is listed on the Nasdaq exchange.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on MTFB.
ChartMill assigns a fundamental rating of 1 / 10 to MTFB. Both the profitability and financial health of MTFB have multiple concerns.
Over the last trailing twelve months MTFB reported a non-GAAP Earnings per Share(EPS) of -0.07. The EPS increased by 63.16% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -570.58% | ||
| ROE | N/A | ||
| Debt/Equity | -0.37 |